Related Experiment Video

Updated: May 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy

Monica Civallero1, Maria Cosenza, Luigi Marcheselli

  • 1University of Modena, 1-Program of Innovative Therapies in Oncology and Haematology, Centro Oncologico Modenese, Department of Oncology and Haematology, Largo del Pozzo 71, 41100 Modena, Italy.

Expert Opinion on Investigational Drugs
|August 28, 2012
PubMed
Abstract

Insights

NVP-BEZ235 effectively inhibits mantle cell lymphoma (MCL) growth by inducing apoptosis and cell cycle arrest. Combinations with other agents enhance its anti-cancer effects, supporting clinical trials for MCL treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mantle cell lymphoma (MCL) is a B-cell malignancy with high response rates to current therapies.
  • The PI3K/Akt/mTOR signaling pathway is implicated in MCL pathogenesis.
  • Targeting this pathway presents a therapeutic opportunity for MCL.

Purpose of the Study:

  • To evaluate the inhibitory effects of NVP-BEZ235 on mantle cell lines.
  • To assess the efficacy of NVP-BEZ235 in combination with enzastaurin, everolimus, and perifosine.
  • To investigate the impact of NVP-BEZ235 on cell proliferation, apoptosis, and cell cycle progression in MCL.

Main Methods:

  • MTT assay and flow cytometry for proliferation and apoptosis.
  • BrdU incorporation for cell cycle analysis.
  • Western blot for protein kinase phosphorylation.
  • Chou-Talalay method for drug interaction analysis.

Main Results:

  • NVP-BEZ235 significantly increased apoptosis via intrinsic and extrinsic pathways.
  • NVP-BEZ235 inhibited MCL cell growth by inducing G1 arrest.
  • NVP-BEZ235 demonstrated antitumor activity in the bone marrow microenvironment.
  • Combination therapies enhanced NVP-BEZ235-induced cytotoxicity.

Conclusions:

  • NVP-BEZ235 shows significant anti-MCL activity.
  • Combination therapy with NVP-BEZ235 warrants further clinical investigation.
  • NVP-BEZ235 may be a promising agent for Phase I/II trials in mantle cell lymphoma patients.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...